Form 4: Forte Biosciences CEO Acquires 920,000 Stock Options
SEC Form 4 Filing
Paul A. Wagner, CEO of Forte Biosciences, reports the acquisition of 920,000 stock options on March 20, 2025.
Summary
- Paul A. Wagner, CEO, Secretary, and Chair of the Board of Forte Biosciences, Inc., filed a Form 4 on March 21, 2025.
- The report details the acquisition of 920,000 stock options with an exercise price of $7.54 on March 20, 2025.
- These options vest monthly over three years, starting January 1, 2025, contingent upon Wagner remaining a service provider.
- The options expire on March 20, 2035.
- Wagner directly owns these derivative securities.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. It reflects a standard executive compensation practice, indicating confidence in the company's future.
Positives
- The acquisition of stock options by the CEO could align his interests with those of the shareholders, incentivizing him to improve the company's performance.
Future Outlook
The vesting schedule of the options suggests a commitment from the CEO for the next three years, contingent on continued service.
Industry Context
Stock option grants are a common practice in the biotechnology industry to incentivize executives and align their interests with shareholders.
Comparison to Industry Standards
- Stock option grants are a typical component of executive compensation packages in the biotech industry.
- Companies like Amgen, Gilead, and Biogen also use stock options to incentivize their leadership teams.
- The vesting schedule of three years is fairly standard, aligning with typical performance evaluation cycles.
Stakeholder Impact
- Shareholders may view the stock option grant as a positive sign, aligning management's interests with theirs.
- Employees may see this as a sign of stability and commitment from the CEO.
Key Dates
| Date | Description |
|---|---|
| January 1, 2025 | Vesting Commencement Date for the stock options. |
| March 20, 2025 | Transaction date for the acquisition of stock options. |
| March 21, 2025 | Date of Form 4 filing. |
| March 20, 2035 | Expiration date of the stock options. |
Keywords
Forte Biosciences, Stock Options, Form 4, CEO, Paul A. Wagner, Equity Incentive Plan, Beneficial Ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.